Brief: Epigenomics Q2 net loss widens to 3.3 mln euros
10/08/2016 06:30
Aug 10 (Reuters) - Epigenomics AG ECXn.DE :
* Announces 2016 second quarter and six months financial results and reports on operational
highlights
* Revenue increased by 159 percent in Q2 2016 over same period prior year
* EBITDA in Q2 2016 was at -3.5 million euros (Q2 2015: -2.2 million euros)
* Net loss amounted to 3.3 million euros in Q2 2016 compared to 2.5 million euros in Q2 2015
* Confirms revenue outlook for current financial year
* Epigenomics expects its liquid assets (incl. marketable securities) of 13.2 million euros
($14.72 million) at reporting date to be sufficient to fund operations well into 2017
* Expect FY EBITDA to be in range of -9.5 million to -11.5 million euros
Source text for Eikon: ID:nEQccX64ca
Further company coverage: ECXn.DE
($1 = 0.8969 euros)
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns